Intellia Therapeutics (LTS:0JBU) EV-to-Revenue : 32.62 (As of May. 25, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Intellia Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Intellia Therapeutics's enterprise value is $1,716.02 Mil. Intellia Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $52.60 Mil. Therefore, Intellia Therapeutics's EV-to-Revenue for today is 32.62.

The historical rank and industry rank for Intellia Therapeutics's EV-to-Revenue or its related term are showing as below:

LTS:0JBU' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.22 Med: 27.58 Max: 345.73
Current: 32.62

During the past 10 years, the highest EV-to-Revenue of Intellia Therapeutics was 345.73. The lowest was 3.22. And the median was 27.58.

LTS:0JBU's EV-to-Revenue is ranked worse than
72.67% of 1039 companies
in the Biotechnology industry
Industry Median: 8.18 vs LTS:0JBU: 32.62

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-25), Intellia Therapeutics's stock price is $25.08. Intellia Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.57. Therefore, Intellia Therapeutics's PS Ratio for today is 43.92.

Intellia Therapeutics EV-to-Revenue Historical Data

The historical data trend for Intellia Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intellia Therapeutics EV-to-Revenue Chart

Intellia Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

11.02

52.51

246.05

37.93

56.20

Intellia Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-Revenue	Get a 7-Day Free Trial															46.30	53.11	40.20	56.20	37.44

Competitive Comparison of Intellia Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, Intellia Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Intellia Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intellia Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Intellia Therapeutics's EV-to-Revenue falls into.

Intellia Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Intellia Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	1716.018	/	52.604
	=	32.62

Intellia Therapeutics's current Enterprise Value is $1,716.02 Mil.
Intellia Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $52.60 Mil.

Intellia Therapeutics (LTS:0JBU) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Intellia Therapeutics's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	25.08	/	0.571
	=	43.92

Intellia Therapeutics's share price for today is $25.08.
Intellia Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.57.

Intellia Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Intellia Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Intellia Therapeutics (LTS:0JBU) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intellia Therapeutics Inc (LTS:0JBU) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

NTLA:USA 38I:Germany

Address

40 Erie Street, Suite 130, Cambridge, MA, USA, 02139

Website

https://www.intelliatx.com

Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Intellia Therapeutics (LTS:0JBU) Headlines

No Headlines